Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

Polpharma Biologics gains FDA and EMA review acceptances

3 August 2026 · By · Wire by Fusion42

Published

3 August 2026

Topic

regulatory

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at pharmatimes.com →

◆ Verified

Fusion42 · 3 August 2026 · Fusion42 review

Polpharma Biologics has received FDA and EMA acceptance for review of its PB016 vedolizumab biosimilar applications, marking a significant step in making affordable biologic treatments available for ulcerative colitis and Crohn's disease.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You have a new route to enter the inflammatory bowel disease treatment market as regulatory gateways open for affordable biosimilar vedolizumab. This clearance shifts competition by lowering barriers to biologic therapy provision.

◆ Coverage

1 source · 3 Aug 2026

◆ Related on Wire

◆ Topics

BiotechbiosimilarsFDA-approvalEMA-approvalinflammatory-bowel-diseasebiologic-medicines